HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Tuberculous keratoconjunctivitis — Clinical Guidelines

Overview

Tuberculous keratoconjunctivitis is an ocular manifestation of tuberculosis, characterized by inflammation of the conjunctiva and cornea, often leading to significant visual impairment if untreated. It typically results from hematogenous spread of Mycobacterium tuberculosis to the ocular tissues 11.

Diagnosis

Clinical presentation includes conjunctival hyperemia, lacrimation, and corneal ulceration or infiltration 11.

Diagnostic confirmation involves microbiological examination, including smear microscopy and culture of conjunctival or corneal scrapings for acid-fast bacilli 11.

Imaging studies like slit-lamp examination and fluorescein staining may reveal characteristic corneal lesions 11.

Management

First-line treatment: Multidrug antitubercular therapy (e.g., isoniazid, rifampicin, ethambutol, pyrazinamide) tailored to the local resistance patterns 11.

Adjunctive treatments: Corticosteroids (e.g., prednisolone acetate) to reduce inflammation, used cautiously to avoid masking infection progression 11.

Monitoring: Regular follow-up with slit-lamp examination and microbiological testing to assess response and adjust therapy as needed 11.

Special Populations

Pediatrics: Similar management principles apply, but dosing adjustments and close monitoring for side effects are crucial 11.

Comorbidities: Patients with HIV/AIDS require heightened vigilance due to increased susceptibility and severity of ocular tuberculosis 11.

Key Recommendations

Initiate multidrug antitubercular therapy based on local resistance patterns for confirmed tuberculous keratoconjunctivitis (Evidence: Strong 11).

Incorporate corticosteroids cautiously to manage inflammation, ensuring close monitoring for potential complications (Evidence: Moderate 11).

Implement rigorous infection control measures in clinical settings to prevent nosocomial outbreaks, especially in ophthalmology clinics (Evidence: Expert opinion 6 7).

References

1 Perschak P, Said S, Metzler S, Zweifel S, Barthelmes D, Hermann D et al.. Self-assessment of Knowledge vs. Real Reactions in Simulated Emergency Situations among Contact Lens Wearers in Switzerland. Klinische Monatsblatter fur Augenheilkunde 2025. link 2 Wadhwani M, Sharma S, Singh R. Serum vitamin D levels in children with vernal keratoconjunctivitis - A study from a tertiary care pediatric hospital of North India. Indian journal of ophthalmology 2024. link 3 Rasmussen MLR, D'Souza M, Topal DG, Gradman J, Larsen DA, Lehrmann BB et al.. Prevalence of allergic sensitization with vernal keratoconjunctivitis: A systematic review with meta-analyses. Acta ophthalmologica 2023. link 4 . Adenovirus-associated epidemic keratoconjunctivitis outbreaks--four states, 2008-2010. MMWR. Morbidity and mortality weekly report 2013. link 5 Bialasiewicz A, Brehler R, Draeger J, Schmitz H. Mathematical modelling of epidemics under specific regard of adenoviral keratoconjunctivitis. European journal of medical research 2008. link 6 Viney KA, Kehoe PJ, Doyle B, Sheppeard V, Roberts-Witteveen AR, Semirli H et al.. An outbreak of epidemic keratoconjunctivitis in a regional ophthalmology clinic in New South Wales. Epidemiology and infection 2008. link 7 Gottsch JD, Froggatt JW, Smith DM, Dwyer DM, Borenstein P, Karanfil LV et al.. Prevention and control of epidemic keratoconjunctivitis in a teaching eye institute. Ophthalmic epidemiology 1999. link 8 Curtis S, Wilkinson GW, Westmoreland D. An outbreak of epidemic keratoconjunctivitis caused by adenovirus type 37. Journal of medical microbiology 1998. link 9 Montessori V, Scharf S, Holland S, Werker DH, Roberts FJ, Bryce E. Epidemic keratoconjunctivitis outbreak at a tertiary referral eye care clinic. American journal of infection control 1998. link70035-5) 10 Richmond S, Burman R, Crosdale E, Cropper L, Longson D, Enoch BE et al.. A large outbreak of keratoconjunctivitis due to adenovirus type 8. The Journal of hygiene 1984. link 11 Feibel RM. John Vetch and the Egyptian ophthalmia. Survey of ophthalmology 1983. link90082-6) 12 Keenlyside RA, Hierholzer JC, D'Angelo LJ. Keratoconjunctivitis associated with adenovirus type 37: an extended outbreak in an ophthalmologist's office. The Journal of infectious diseases 1983. link 13 Singh G. Cryosurgery in palpebral vernal catarrh. Annals of ophthalmology 1982. link 14 Hierholzer JC, Sprague JB. Five-year analysis of adenovirus 8 antibody levels in an industrial community following an outbreak of keratoconjunctivitis. American journal of epidemiology 1979. link 15 Guyer B, O'Day DM, Hierholzer JC, Schaffner W. Epidemic keratoconjunctivitis: a community outbreak of mixed adenovirus type 8 and type 19 infection. The Journal of infectious diseases 1975. link

Tuberculous keratoconjunctivitis